<?xml version='1.0' encoding='utf-8'?>
<document id="12616661"><sentence text="Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature."><entity charOffset="31-40" id="DDI-PubMed.12616661.s1.e0" text="lidocaine" /></sentence><sentence text="The safety, tolerability, and efficacy of the lidocaine patch 5% (Lidoderm), a targeted peripheral analgesic with an FDA-approved indication for the treatment of postherpetic neuralgia, has been well established"><entity charOffset="46-55" id="DDI-PubMed.12616661.s2.e0" text="lidocaine" /></sentence><sentence text=" Recent case reports and studies have suggested potential efficacy in other neuropathic and nonneuropathic pain conditions" /><sentence text=" Several pharmacokinetic studies have demonstrated minimal systemic absorption with 12-, 18-, and 24-hour/day dosing" /><sentence text=" Mean maximum plasma concentrations have shown the lidocaine patch to possess a minimal risk for systemic toxicities or drug-drug interactions"><entity charOffset="51-60" id="DDI-PubMed.12616661.s5.e0" text="lidocaine" /></sentence><sentence text=" The most common adverse events generally involve mild skin reactions" /><sentence text=" There have been no drug-drug interactions noted in clinical trials" /><sentence text=" Recent evidence suggests that extended application does not result in A-beta-mediated sensory loss at the application site, which is particularly important in patients who already have a degree of sensory loss due to their underlying condition" /><sentence text=" The lidocaine patch provides a treatment option that carries a relatively low systemic adverse event and drug-drug interaction risk burden, even with continuous application of up to four patches per day"><entity charOffset="5-14" id="DDI-PubMed.12616661.s9.e0" text="lidocaine" /></sentence><sentence text="" /></document>